Viatris
Tracked across 3 events · 53 articles · First seen Apr 04, 2025 · Last active Jul 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Viatris received FDA approval for Gwyn Lo, a new once-weekly contraceptive patch with low-dose estrogen, expanding its women's health portfolio. The approval is a positive regulatory milestone, though commercial impact depends on launch timing, pricing, and payer coverage.
Jul 29, 2026 · 6 articles
Business
Impact: Viatris is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Feb 26, 2026 · 7 articles
Business
Impact: Biocon acquired Viatris' global biosimilars business for over $3 billion, consolidating its position in the market.
May 05, 2026 · 40 articles
ERGEN INTELLIGENCE
Track Viatris live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard